A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE DOSE, 5-WAY CROSSOVER STUDY ASSESSING THE PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILES OF ORAL INHALED PF-03635659 IN PATIENTS WITH MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK0 个研究点目标入组 20 人开始时间: 2009年11月19日最近更新: 2013年1月28日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 20

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Male or female (women of non-childbearing potential) subjects between the ages of 40 and 80 years, inclusive with a diagnosis of moderate COPD (GOLD, 2007 update) and who meet the following criteria for GOLD stage II disease:
•Post-bronchodilator FEV1/FVC ratio of <0.7, and a
•Post bronchodilator FEV1 of 50-80% (inclusive) of predicted for age, height, sex and race.
•Note: Subjects who are maintained on LABA, Spiriva® or ipratropium should have a washout period of at least 48, 72 and 24 hours respectively before undergoing the screening post-bronchodilator test.
•2. Body Mass Index (BMI) of less than 35.5 kg/m2; and a total body weight >40 kg (88 lbs).
•3. Subjects must have a smoking history of at least 10 pack-years (Formula for pack-years cigarettes = (average number of cigarettes/day ÷ 20) x years of smoking. Formula for pack-years tobacco = ounces per week x 2/7 x years of smoking) and meet one of the following criteria:
•They are current smokers, or
•They are ex-smokers who have abstained from smoking for at least 6 months.
•4. Subjects must have stable disease for at least 1 month prior to screening. Subjects must be able to manage their symptoms adequately with short-acting bronchodilators only. (Salbutamol as needed, maximum of 8 actuations (100 mcg/actuation) daily). Subjects currently maintained on LABA and/or Spiriva®, must agree to withdraw these drugs at least 2 weeks prior to study Period 1 and must be able to manage their symptoms with salbutamol as stated above. (During the LABA and/or Spiriva® wash out period subjects will be contacted by telephone to check their stability).
•5. An informed consent document signed and dated by the subject or a legally acceptable representative.
•6. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Subjects presenting with any of the following will not be included in the study:
•1. Subjects having more than 2 exacerbation requiring treatment with oral steroids or hospitalization for the treatment of COPD in the previous year.
•2. Use of prescription or non-prescription drugs as follows:
•Subjects on medication (other than salbutamol) having a significant effect on cardiac rate, conduction system (including QT interval) or myocardial function.
•Subjects on inhaled corticosteroids.
•3. Subjects with uncontrolled hypertension. Stable hypertensive subjects are permitted but must remain on their anti-hypertensive medication through out the study and not change drug, regime or dose etc during the trial.
•4. History of lower respiratory tract infection or significant disease instability during the month preceding screening or during the period between screening and randomization.
•5. History or presence of respiratory failure, cor pulmonale or right ventricular failure.
•6. Apart from COPD, any clearly documented history of adult asthma (onset of symptoms prior to the age of 40 years) or other chronic respiratory disorders (eg, bronchiectasis, pulmonary fibrosis, pneumoconiosis.
•7. Abnormal 12-lead ECG including evidence of ischaemia, myocardial infarction, arrhythmia or QTc >450 msec. (If QTc exceeds these limits, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject’s eligibility). Patients with familial long QT syndrome are also excluded.
•8. A resting pulse rate >100 bpm or <50 bpm.
•9. History within the previous year of: myocardial infarction, cardiac arrhythmia (eg, atrial fibrillation, paroxysmal atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia), cardiac insufficiency NYHA II-IV, left ventricular failure, unstable angina, coronary angioplasty, or coronary artery bypass grafting (CABG).
•10. Any of the following liver function test abnormalities that persist on retesting:
•Alanine amino transferase >1.5 x upper limit of normal (ULN).
•Aspartate amino transferase >1.5 x ULN.
•Alkaline phosphatase >1.2 x ULN.
•Total bilirubin >1.5 x ULN.
•11. Use of any investigational drug within 6 weeks prior to dosing.
•12. History of severe drug induced hypersensitivity (ie, anaphylaxis).
•13. A positive urine drug screen.
•14. History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for men (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of spirits) within 6 months of screening.
•15. Pregnant or nursing females and females of childbearing potential.
•16. Subjects with a known intolerance to lactose, ipratropium, Spiriva® (tiotropium bromide) or any of the listed rescue medications.
•17. Subjects in whom antimuscarinic agents are contraindicated or who suffer from hypersensitivity to Spiriva®, atropine or its derivatives, eg, ipratropium or oxitropium or to the excipient lactose monohydrate which contains milk protein.
•18. Subjects suffering narrow-angle glaucoma, benign prostatic hyperplasia or bladder-neck obstruction.
•19. Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.
•20. Unwilling or unable to comply with the Lifestyle guidelines described in this protocol.
•21. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with t

研究者

发起方

Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK

相似试验

进行中（未招募）

不适用

A trial to compare Z102 against placebo in patients with Rheumatoid Arthritis.Treatment of patients with moderate to severe rheumatoid arthritis (RA)MedDRA version: 14.1Level: HLTClassification code 10039075Term: Rheumatoid arthritis and associated conditionsSystem Organ Class: 10021428 - Immune system disorders

EUCTR2011-000436-28-BGZalicus, Inc.250

进行中（未招募）

不适用

EUCTR2011-000436-28-HUZalicus, Inc.250

进行中（未招募）

不适用

EUCTR2011-000436-28-PLZalicus, Inc.250

未知

不适用

A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF GDC-0941 OR GDC-0980 WITH FULVESTRANT VERSUS FULVESTRANT IN ADVANCED OR METASTATIC BREAST CANCER IN PATIENTS RESISTANT TO AROMA TASE INHIBITOR THERAPY

PER-032-12GENENTECH, INC.,2

进行中（未招募）

不适用

Study of the novel cancer drug GDC-0941 (or placebo) in combination with : a) the approved anticancer drugs carboplatin and paclitaxel; and b) the approved anticancer drugs carboplatin, paclitaxel and bevacizumab in previously untreated patients with advanced non-small cell lung cancerPREVIOUSLY UNTREATED ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCERMedDRA version: 16.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2011-002893-21-GBGenentech, Inc.496